Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ghavamzadeh, Ardeshir  [Clear All Filters]
2023
Ahmadvand M, Barough MShokrollah, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, Rajaienejad M, Majidzadeh K, Ghavamzadeh A, Sarrami-Forooshani R. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.
Ahmadvand M, Barough MShokrollah, Hashemi ZSadat, Sanati H, Abbasvandi F, Yunesian M, Majidzadeh-A K, Makarem J, Aghayan HReza, Abedini A, et al. Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19. Pilot Feasibility Stud. 2023;9(1):137.
Barkhordar M, Chahardouli B, Biglari A, Ahmadvand M, Bahri T, Alaeddini F, Aliabadi LSharifi, Noorani SSaeid, Amiri FBagheri, Biglari M, et al. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study. Front Immunol. 2023;14:1169666.
2022
Alizadehasl A, Ghadimi N, Hosseinifard H, Roudini K, Emami AHossein, Ghavamzadeh A, Khoda-Amorzideh D. Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis. Curr Res Transl Med. 2022;71(1):103363.
Vaezi M, Souri M, Setarehdan SAmin, Hamidieh AAli, Fazlollahi MReza, Pourpak Z, Badalzadeh M, Tajik S, Mahdaviani SAlireza, Alimoghaddam K, et al. A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review. Ann Hematol. 2022.
Kiumarsi A, Mousavi SAli, Kasaeian A, Rostami T, Rad S, Ghavamzadeh A, Mousavi SAsadollah. Radiation-free Reduced-intensity Hematopoietic Stem Cell Transplantation with In-Vivo T-cell Depletion from Matched Related and Unrelated Donors for Fanconi Anemia: Prognostic Factor Analysis. Exp Hematol. 2022.
2020
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
2019
Mousavi SAsadollah, Kasaeian A, Pourkasmaee M, Ghavamzadeh A, Alimoghaddam K, Vaezi M, Fumani HKamranzade, Babakhani D, Tavakoli S. Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. PLoS One. 2019;14(1):e0208701.
Mohammed J, Aljurf M, Althumayri A, Almansour M, Alghamdi A, Hamidieh AAli, Elhaddad A, Ben Othman T, Bazarbachi A, Almohareb F, et al. Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. Hematol Oncol Stem Cell Ther. 2019.
2018
Izadifard M, Pashaiefar H, Yaghmaie M, Montazeri M, Sadraie M, Momeny M, Jalili M, Ahmadvand M, Ghaffari SHamidollah, Mohammadi S, et al. Expression Analysis of PVT1, CCDC26, and CCAT1 Long Noncoding RNAs in Acute Myeloid Leukemia Patients. Genet Test Mol Biomarkers. 2018.
Momeny M, Eyvani H, Barghi F, Ghaffari SH, Javadikooshesh S, Jamadi RH, Esmaeili F, Alishahi Z, Zaghal A, Bashash D, et al. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells. Anticancer Drugs. 2018.
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R-M, Niederwieser D, Volin L, Markiewicz M, Arnold R, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis. J Intern Med. 2018.
2016
Eyvani H, Moghaddaskho F, Kabuli M, Zekri A, Momeny M, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Arsenic trioxide induces cell cycle arrest and alters DNA methylation patterns of cell cycle regulatory genes in colorectal cancer cells. Life Sci. 2016.
Hamidieh AA, Hamidi Z, Behfar M, Pajouhi Z, Alimoghaddam K, Mohseni F, Ghavamzadeh A, Sobhani M, Larijani B, Tehrani MRMohajeri. How is the relation between endocrine changes and bone markers in pediatric thalassemic patients after Hematopoietic Stem Cell Transplantation. Minerva Pediatr. 2016.
Vaezi M, Gharib C, Souri M, Ghavamzadeh A. Late Complications in acute Leukemia patients following HSCT: A single center experience. Int J Hematol Oncol Stem Cell Res. 2016;10(1):1-6.
Dizaji MZaki, Ghaffari SH, Hosseini E, Alizadeh N, Rostami S, Momeny M, Alimoghaddam K, Ghavamzadeh A. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α. Asia Pac J Clin Oncol. 2016.
2015
Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A. Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia. Hematol Oncol. 2015.
2014
Zeighami S, Hadjibabaie M, Ashouri A, Sarayani A, Khoee SHamid, Mousavi S, Radfar M, Ghavamzadeh A. Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation. Iran J Pharm Res. 2014;13(1):305-12.
Hamidieh AAli, Mohajeri-Tehrani MReza, Behfar M, Vaghari-Meher N, Alimoghaddam K, Mohseni F, Ghavamzadeh A, Larijani B, Hamidi Z. Comparison of Bone Mineral Density Changes in Pediatric Thalassemic Patients With and Without Hematopoietic Stem Cell Transplant. Exp Clin Transplant. 2014.
Taati B, Snoek J, Aleman D, Ghavamzadeh A. Data mining in bone marrow transplant records to identify patients with high odds of survival. IEEE J Biomed Health Inform. 2014;18(1):21-7.
Ataei S, Hadjibabaie M, Moslehi A, Taghizadeh-Ghehi M, Ashouri A, Amini E, Gholami K, Hayatshahi A, Vaezi M, Ghavamzadeh A. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2014.
Jalali A, Alimoghaddam K, Mahmoudi M, Mohammad K, Mousavi SAsadollah, Bahar B, Vaezi M, Zeraati H, Jahani M, Ghavamzadeh A. The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks. Int J Hematol Oncol Stem Cell Res. 2014;8(2):1-8.
Alimoghaddam K, Jalali A, Aliabadi LSharifi, Ghaffari F, Maheri R, Eini E, Mashhadireza M, Mousavi SAsadollah, Bahar B, Jahani M, et al. The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience. Int J Hematol Oncol Stem Cell Res. 2014;8(2):9-13.
2013
Ghavamzadeh A, Alimoghaddam K, Ghaffari F, Derakhshandeh R, Jalali A, Jahani M. Twenty years of experience on stem cell transplantation in iran. Iran Red Crescent Med J. 2013;15(2):93-100.
Ghehi MTaghizadeh, Rezaee S, Hayatshahi A, Hadjibabaie M, Gholami K, Javadi M, Khoee SHamid, Radfar M, Esfandbod M, Ghavamzadeh A. Vancomycin Pharmacokinetic Parameters in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7(4):1-9.